See every side of every news story
Published loading...Updated

QALSODY™ (tofersen injection) Receives Conditional Marketing Authorization from Health Canada as the First ALS Treatment Targeting a Genetic Cause - Life Sciences British Columbia

Summary by lifesciencesbc.ca
QALSODY targets the root cause of SOD1-ALS, an ultra-rare and uniformly fatal neurodegenerative disease marked by motor neuron loss in the brain and spinal cord1 Biogen’s second rare disease therapy to be approved in Canada reflects a continued commitment to advancing innovative therapies for diseases with high unmet medical need TORONTO, ON –  Biogen Canada Inc. announced that Health Canada has issued marketing authorization with conditions (N…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

lifesciencesbc.ca broke the news in on Monday, March 3, 2025.
Sources are mostly out of (0)

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.